We would like to inform you that due to unforeseen circumstances beyond the organizer control, the "12th Edition of the Global Conference on Pharmaceutics and Novel Drug Delivery Systems" (Pharma-2025), originally scheduled for March 13-15, 2025 | Hybrid Event has been postponed. The updated dates and venue are September 11-13, 2025 | Valencia, Spain. For more details, please visit: https://pharmaceuticsconference.com/
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at pharmadds@magnusconference.com or call + 1 (702) 988 2320.
The targeted localization of maximal concentrations of the therapeutic to the cellular/subcellular site of action in pathologically damaged tissues is one of the recurring obstacles in therapeutic drug delivery. Small molecule medications lack tissue and organ selectivity, have quick in vivo body clearance, and are frequently associated with a slew of adverse effects, particularly chemotherapeutic treatments, which are extremely toxic. Drug delivery systems (DDS) have been employed as one of the most promising solutions to solve this issue in recent decades. Cell-mediated DDS has emerged as a promising technique for addressing the aforementioned issues in recent years. Cell-mediated DDS has emerged as a new branch of therapy that allows for tailored distribution, increased circulation time, and decreased cellular and tissue toxicity. Intracellular delivery/therapy is a critical topic that will pique people's curiosity. Because the drug is not provided externally within the bloodstream, intracellular delivery allows for far more efficient drug delivery because the impact (on various organelles and locations) is intracellular. Targeted delivery with increased localized delivery and efficacy has a lot of potential.
Title : Liver biopsy handling of Metabolic-Associated Fatty Liver Disease (MAFLD): The children's hospital of eastern Ontario grossing protocol
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Haptoglobin-Related Protein Without Signal Peptide as biomarker of renal salt wasting (HPRWSP) in hyponatremia, hyponatremia-related diseases and as new syndrome in alzheimer’s disease
John K Maesaka, NYU Langone Hospital Long Island, United States
Title : Enabling knowledge-driven integration and interoperability in intelligent and ethical transformed health ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets. Discovery of agonists and antagonists of OR51E1, an understudied G Protein-Coupled Receptor
Vladlen Slepak, University of Miami, United States
Title : Revolutionizing healthcare and pharma: Artificial intelligence-powered scientific communications and medical writing
Alessandro Gallo, Springer Healthcare, Italy
Title : Understanding drug transport in plasma: the role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model to be set up via biodesign-driven biotech and upgraded biomarketing to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Cell viability assays under radiofrequency application modulated by nanomaterials
Paulo C De Morais, Catholic University of Brasilia, Brazil
Title : Preparation and characterization of fibers made from PCL/PVP-ChAgG, along with exploring their potential as wound dressings
Luis Jesus Villarreal Gomez, Autonomous University of Baja California, Mexico
Title : Biosimilars - The current progress
Miroslav Radenkovic, University of Belgrade, Serbia